Literature DB >> 17356069

Endofin acts as a Smad anchor for receptor activation in BMP signaling.

Weibin Shi1, Chenbei Chang, Shuyi Nie, Shutao Xie, Mei Wan, Xu Cao.   

Abstract

Signaling through receptors of the transforming growth factor beta (TGFbeta) superfamily is mediated by cytoplasmic Smad proteins. It has been demonstrated that Smad anchor for receptor activation (SARA) facilitates TGFbeta and activin/nodal signaling by recruiting and presenting Smad2/3 to the receptor complex. SARA does not bind Smad1 and hence does not enhance bone morphogenetic protein (BMP) signaling. Here we report for the first time that the endosome-associated FYVE-domain protein endofin acts as a Smad anchor for receptor activation in BMP signaling. We demonstrate that endofin binds Smad1 preferentially and enhances Smad1 phosphorylation and nuclear localization upon BMP stimulation. Silencing of endofin by RNAi resulted in a reduction in BMP-dependent Smad1 phosphorylation. Moreover, disruption of the membrane-anchoring FYVE motif by point mutation led to a reduction of BMP-responsive gene expression in cell culture and Xenopus ectodermal explants. Furthermore, we demonstrate that endofin contains a protein-phosphatase-binding motif, which functions to negatively modulate BMP signals through receptor dephosphorylation. Taken together, our results suggest that endofin plays an important role in both positive and negative feedback regulation of the BMP signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17356069     DOI: 10.1242/jcs.03400

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  36 in total

1.  Initiation of BMP2 signaling in domains on the plasma membrane.

Authors:  Jeremy Bonor; Elizabeth L Adams; Beth Bragdon; Oleksandra Moseychuk; Kirk J Czymmek; Anja Nohe
Journal:  J Cell Physiol       Date:  2012-07       Impact factor: 6.384

Review 2.  Structural determinants of Smad function in TGF-β signaling.

Authors:  Maria J Macias; Pau Martin-Malpartida; Joan Massagué
Journal:  Trends Biochem Sci       Date:  2015-04-29       Impact factor: 13.807

Review 3.  Bone morphogenetic proteins and their antagonists: current and emerging clinical uses.

Authors:  Imran H A Ali; Derek P Brazil
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

Review 4.  Specificity, versatility, and control of TGF-β family signaling.

Authors:  Rik Derynck; Erine H Budi
Journal:  Sci Signal       Date:  2019-02-26       Impact factor: 8.192

Review 5.  Biology of BMP signalling and cancer.

Authors:  M Blanco Calvo; V Bolós Fernández; V Medina Villaamil; G Aparicio Gallego; S Díaz Prado; E Grande Pulido
Journal:  Clin Transl Oncol       Date:  2009-03       Impact factor: 3.405

Review 6.  TGF-β Signaling from Receptors to Smads.

Authors:  Akiko Hata; Ye-Guang Chen
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-09-01       Impact factor: 10.005

7.  Hereditary spastic paraplegia-causing mutations in atlastin-1 interfere with BMPRII trafficking.

Authors:  Jiali Zhao; Peter Hedera
Journal:  Mol Cell Neurosci       Date:  2012-10-16       Impact factor: 4.314

8.  Myotubularin-related protein 4 (MTMR4) attenuates BMP/Dpp signaling by dephosphorylation of Smad proteins.

Authors:  Junjing Yu; Xiaomeng He; Ye-Guang Chen; Yan Hao; Shuo Yang; Lei Wang; Lei Pan; Hong Tang
Journal:  J Biol Chem       Date:  2012-11-13       Impact factor: 5.157

9.  TGF-beta signaling proteins and the Protein Ontology.

Authors:  Cecilia N Arighi; Hongfang Liu; Darren A Natale; Winona C Barker; Harold Drabkin; Judith A Blake; Barry Smith; Cathy H Wu
Journal:  BMC Bioinformatics       Date:  2009-05-06       Impact factor: 3.169

10.  The hereditary spastic paraplegia proteins NIPA1, spastin and spartin are inhibitors of mammalian BMP signalling.

Authors:  Hilda T H Tsang; Thomas L Edwards; Xinnan Wang; James W Connell; Rachel J Davies; Hannah J Durrington; Cahir J O'Kane; J Paul Luzio; Evan Reid
Journal:  Hum Mol Genet       Date:  2009-07-20       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.